Mavoglurant
- Generic Name
- Mavoglurant
- Drug Type
- Small Molecule
- Chemical Formula
- C19H23NO3
- CAS Number
- 543906-09-8
- Unique Ingredient Identifier
- GT0I9SV4F6
- Background
Mavoglurant has been used in trials studying the treatment of Patient Diagnosed With OCD and and Resistant to SSRI Treatment (Failed SSRI Over 12 Weeks at Appropriate Doses).
Tempero Bio Secures $70M Series B to Advance Novel Addiction Treatment Through Phase 2 Trials
• Tempero Bio has raised $70 million in Series B financing to advance TMP-301, a novel mGluR5 negative allosteric modulator targeting the neurobiological basis of addiction, through Phase 2 clinical trials.
• The company has already initiated a Phase 2 trial for alcohol use disorder and plans to begin cocaine use disorder studies within the next year, addressing conditions that affect millions of Americans with limited treatment options.
• Industry veteran John Wagner, M.D., Ph.D., with over 20 years of drug development experience, will join Tempero Bio as Chief Medical Officer to oversee the clinical advancement of TMP-301.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath